MX2018015112A - Composiciones de nanoemulsión de fármacos taxoides, y métodos para su uso para actuar sobre células cancerosas y células madre cancerosas. - Google Patents

Composiciones de nanoemulsión de fármacos taxoides, y métodos para su uso para actuar sobre células cancerosas y células madre cancerosas.

Info

Publication number
MX2018015112A
MX2018015112A MX2018015112A MX2018015112A MX2018015112A MX 2018015112 A MX2018015112 A MX 2018015112A MX 2018015112 A MX2018015112 A MX 2018015112A MX 2018015112 A MX2018015112 A MX 2018015112A MX 2018015112 A MX2018015112 A MX 2018015112A
Authority
MX
Mexico
Prior art keywords
drug
methods
cancer
cancer stem
pufa
Prior art date
Application number
MX2018015112A
Other languages
English (en)
Spanish (es)
Inventor
E Egan James
Ojima Iwao
M Amiji Mansoor
Ivanovna BOTCHKINA Galina
Original Assignee
Targagenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targagenix Inc filed Critical Targagenix Inc
Publication of MX2018015112A publication Critical patent/MX2018015112A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2018015112A 2016-06-07 2017-06-07 Composiciones de nanoemulsión de fármacos taxoides, y métodos para su uso para actuar sobre células cancerosas y células madre cancerosas. MX2018015112A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662346755P 2016-06-07 2016-06-07
PCT/US2017/036330 WO2017214260A1 (en) 2016-06-07 2017-06-07 Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells

Publications (1)

Publication Number Publication Date
MX2018015112A true MX2018015112A (es) 2019-09-09

Family

ID=60578981

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015112A MX2018015112A (es) 2016-06-07 2017-06-07 Composiciones de nanoemulsión de fármacos taxoides, y métodos para su uso para actuar sobre células cancerosas y células madre cancerosas.

Country Status (9)

Country Link
US (3) US10206875B2 (cg-RX-API-DMAC7.html)
EP (1) EP3463299A4 (cg-RX-API-DMAC7.html)
JP (1) JP7518604B2 (cg-RX-API-DMAC7.html)
CN (2) CN116019768A (cg-RX-API-DMAC7.html)
AU (1) AU2017277497B2 (cg-RX-API-DMAC7.html)
CA (1) CA3026412A1 (cg-RX-API-DMAC7.html)
IL (1) IL263504A (cg-RX-API-DMAC7.html)
MX (1) MX2018015112A (cg-RX-API-DMAC7.html)
WO (1) WO2017214260A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116019768A (zh) * 2016-06-07 2023-04-28 塔佳吉尼克斯公司 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法
CN112996501A (zh) * 2017-12-20 2021-06-18 塔佳吉尼克斯公司 癌症中紫杉类纳米乳剂与免疫疗法的联合
US20220226480A1 (en) * 2019-03-22 2022-07-21 Integrated Nanotherapeutics Inc. Lipid conjugate prepared from scaffold moiety
AU2020370372A1 (en) * 2019-10-25 2022-05-12 Amgen Inc. Compositions and methods for minimizing protein loss at low protein concentrations
EP4054550A4 (en) * 2019-11-05 2024-01-17 Luminus Biosciences Inc. NANOPARTICLES WITH PRODRUGS STABILIZED BY ALBUMIN FOR THE TREATMENT OF CANCER AND OTHER DISEASES
CN111004195B (zh) * 2019-12-03 2022-01-28 沈阳药科大学 卡巴他赛弱碱性衍生物及其制剂
CN114317398B (zh) * 2020-09-27 2024-03-01 中国科学院分子细胞科学卓越创新中心 Gli1和EpCAM基因共同标记的肝祖细胞群及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
CA2544128A1 (en) * 2003-10-30 2005-05-12 The Research Foundation Of State University Of New York Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
AU2009280803B2 (en) * 2008-07-23 2013-10-31 Bharat Serums And Vaccines Ltd. Stable injectable oil-in-water Docetaxel nanoemulsion
US20100021471A1 (en) * 2008-07-25 2010-01-28 Brookhaven Science Associates, Llc Carbon nanotube-based drug delivery systems and methods of making same
US20140105829A1 (en) * 2012-10-15 2014-04-17 Nemucore Medical Innovations, Inc. Therapeutic nanoemulsion formulation for the targeted delivery of docetaxel and methods of making and using the same
KR102397569B1 (ko) * 2014-06-19 2022-05-12 솔루랄 파마 에이피에스 친유성 화합물의 고형 경구 투여 형태
US10736842B2 (en) * 2014-06-25 2020-08-11 Synergia Bio Sciences Private Limited Pharmaceutical oil-in-water nano-emulsion
CN116019768A (zh) * 2016-06-07 2023-04-28 塔佳吉尼克斯公司 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法
CN112996501A (zh) * 2017-12-20 2021-06-18 塔佳吉尼克斯公司 癌症中紫杉类纳米乳剂与免疫疗法的联合

Also Published As

Publication number Publication date
AU2017277497A1 (en) 2018-12-20
IL263504A (en) 2019-01-31
CA3026412A1 (en) 2017-12-14
USRE50096E1 (en) 2024-08-27
EP3463299A4 (en) 2020-01-15
NZ748915A (en) 2024-09-27
JP7518604B2 (ja) 2024-07-18
EP3463299A1 (en) 2019-04-10
US20250009658A1 (en) 2025-01-09
AU2017277497B2 (en) 2023-05-04
JP2019523226A (ja) 2019-08-22
US20180028442A1 (en) 2018-02-01
WO2017214260A1 (en) 2017-12-14
CN109562065A (zh) 2019-04-02
US10206875B2 (en) 2019-02-19
CN116019768A (zh) 2023-04-28

Similar Documents

Publication Publication Date Title
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
BR112016011169A2 (pt) Método para a produção de células imunes ex vivo que são resistentes a um fármaco análogo de purina, célula t isolada resistente a um análogo de purina, composição farmacêutica e uso das mesmas
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
BR112017011536A2 (pt) terapias de combinação
BR112020009655A8 (pt) Anticorpo, usos de um anticorpo e uso de uma combinação farmacêutica
PH12012502399A1 (en) Combination therapy methods for treating proliferative diseases
MX2019009952A (es) Formulaciones de evolocumab de baja viscosidad y alta concentracion y metodos de elaboracion de las mismas.
BR112015023481A2 (pt) composição de lipossoma de liberação controlada de fármaco
MX393793B (es) Composición farmacéutica que comprende asparaginasa y metioninasa para tratar cáncer.
Montiel-Ruiz et al. Synergistic interactions between the antinociceptive effect of Rhodiola rosea extract and B vitamins in the mouse formalin test
CL2019000018A1 (es) Formas sólidas de un estimulador de sgc.
MY205229A (en) Oral dosage form with drug composition, barrier layer and drug layer
WO2019126302A3 (en) Combination taxoid nanoemulsion with immunotherapy in cancer
TR201821157T4 (tr) İbandroni̇k asi̇t veya bunun farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzu ve d vi̇tami̇ni̇ i̇çeren oral uygulamaya yöneli̇k kati bi̇leşi̇m.
AR110800A1 (es) MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2’-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
CL2015002627A1 (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
MX2018001989A (es) Formulaciones farmaceuticas.
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
WO2015063613A3 (en) Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
Belskaya et al. Possibilities of the treatment of speech impairment in the acute stage of ischemic stroke using neuroprotective therapy
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.